SCHEMBL3269874

SCHEMBL3269874

CNC(=O)COC(=O)NCCC1(F)CCN(c2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.47
LMNA P02545 7/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 4/20 0.44
NPSR1 Q6W5P4 2/20 0.44
TSHR P16473 1/20 0.43
KDM4E B2RXH2 2/20 0.43
MAPT P10636 2/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
HSD17B10 Q99714 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
DRD2 P14416 1/20 0.42
DRD3 P35462 1/20 0.42
HTT P42858 1/20 0.41
GAA P10253 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HTR3E A5X5Y0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3265586 0.83 CHRM4 (0.54) POLBLMNAMEN1KMT2AALDH1A1
SCHEMBL5234744 0.78 ALDH1A1 (0.67) POLBLMNAMEN1KMT2AALDH1A1
SCHEMBL1727690 0.77 POLB (0.44) POLBLMNAMEN1KMT2AALDH1A1
SCHEMBL3265530 0.77 POLB (0.46) POLBLMNAMEN1KMT2AALDH1A1
SCHEMBL241458 0.75 DRD3 (0.41) ALDH1A1KDM4EMAPK1RAB9AHSD17B10
SCHEMBL2979849 0.71 CHRM4 (0.56) SIGMAR1
SCHEMBL240152 0.71 CHRM4 (0.56) POLBLMNAALDH1A1NPSR1TSHR
SCHEMBL11439568 0.70 DRD3 (0.65) POLBLMNAMEN1KMT2AALDH1A1
Hydrochloric Acid SCHEMBL11152886 0.70 DRD3 (0.64) POLBLMNAMEN1KMT2AALDH1A1
SCHEMBL594530 0.68 ALDH1A1 (0.53) POLBLMNAMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES SANOFI-AVENTIS (FR) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 POLB 1541/4885LMNA 901/4885MEN1 1340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.